Skip to main content
Livermore
Livermore
ZHEN

Acrivon Therapeutics, Inc.

ACRV
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001781174

In the last 90 days, Acrivon Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 46 institutions reported holding it in 13F filings for Q2 2026, worth $38.1M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Acrivon Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
8 filings
6 insiders, $39.8K in total
Insiders trading
6
Net value
−$39.8K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Acrivon Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Acrivon Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Levin MichaelaChief Business Officer30,000Sep 2, 20261
Blume-Jensen PeterPresident and CEO2,230,052Aug 27, 202611
Masson KristinaEVP - Business Operations2,230,052Aug 27, 202611
Peterson KatharineChief Accounting Officer18,033Aug 20, 20266
Miller MaryChief Legal Officer82,009Aug 20, 202611
Gamelin ErickChief Development Officer52,592Aug 20, 20266
Devroe EricChief Operating Officer146,349Aug 20, 20267
Levy Adam D.Chief Financial Officer66,008Aug 6, 20264
RA Capital Healthcare Fund LPDirector, 10% Owner9,366IndirectJun 22, 20263
Ra Capital Management, L.P.Director, 10% Owner9,366IndirectJun 22, 20263
Kolchinsky PeterDirector, 10% Owner9,366IndirectJun 22, 20263
Shah Rajeev M.Director, 10% Owner9,366IndirectJun 22, 20263
RA Capital Nexus Fund II, L.P.Director9,366IndirectJun 22, 20263
Magovcevic-Liebisch IvanaDirector9,366Jun 22, 20262
Tomsicek Michael JohnDirector9,366Jun 22, 20262
Baum Charles MDirector9,366Jun 22, 20262
Shacham SharonDirector9,366Jun 22, 20262
DiRocco DerekDirector9,366Jun 22, 20262
Palani SanthoshDirector9,366Jun 22, 20262
Mirza Mansoor RazaChief Medical Officer38,817May 20, 20263
Edelman Joseph10% Owner3,104,139IndirectMay 1, 20250
Perceptive Advisors LLC10% Owner3,104,139IndirectMay 1, 20250
Perceptive Life Sciences Master Fund Ltd10% Owner3,104,139IndirectMay 1, 20250
Cuillerot Jean-MarieChief Medical Officer–Mar 4, 20250
Holm-Jorgensen RasmusChief Financial Officer26,088Mar 4, 20250
Chione Ltd10% Owner3,848,632Jun 28, 20230
Hadjimichael Andreas10% Owner3,848,632Jun 28, 20230
Smolokowski Wiaczeslaw10% Owner3,848,632Jun 28, 20230
Czernik Marcin10% Owner3,848,632Jun 28, 20230
Nikolaou Anastasis10% Owner3,848,632Jun 28, 20230
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.10% Owner888,130Nov 21, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 27, 2026 (view filing)4:14 PM ETAug 252 daysBlume-Jensen Peter and 1 otherPresident and CEOSSale−14.0K$2.21−$31.0K−0.6%2.23M after
Aug 20, 2026 (view filing)4:10 PM ETAug 182 daysPeterson KatharineChief Accounting OfficerSSale−101$2.01−$203.01−0.6%18.0K after
Aug 20, 2026 (view filing)4:09 PM ETAug 182 daysMiller MaryChief Legal OfficerSSale−185$2.01−$371.85−0.2%82.0K after
Aug 20, 2026 (view filing)4:08 PM ETAug 182 daysGamelin ErickChief Development OfficerSSale−400$2.01−$804−0.8%52.6K after
Aug 20, 2026 (view filing)4:07 PM ETAug 182 daysDevroe EricChief Operating OfficerSSale−604$2.01−$1.21K−0.4%146.3K after
Aug 20, 2026 (view filing)4:07 PM ETAug 182 daysBlume-Jensen Peter and 1 otherPresident and CEOSSale−1.23K$2.01−$2.47K−0.1%2.24M after
Aug 20, 2026 (view filing)4:07 PM ETAug 182 daysBlume-Jensen Peter and 1 otherPresident and CEOSSale−484$2.01−$972.84−0.1%385.9K after
Aug 6, 2026 (view filing)4:34 PM ETAug 42 daysLevy Adam D.Chief Financial OfficerSSale−1.14K$1.57−$1.79K−1.7%66.0K after
Jul 23, 2026 (view filing)4:28 PM ETJul 212 daysMiller MaryChief Legal OfficerSSale−573$1.76−$1.01K−0.7%82.2K after
Jan 16, 2026 (view filing)4:02 PM ETJan 142 daysBlume-Jensen Peter and 1 otherPresident and CEOPPurchase+49.0K$1.68+$82.1K+2.4%2.10M after
Jan 16, 2026 (view filing)Jan 142 daysLevy Adam D.Chief Financial OfficerPPurchase+8.83K$1.70+$15.0K+72.7%21.0K after
Jan 15, 2026 (view filing)Jan 132 daysDevroe EricChief Operating OfficerPPurchase+10.0K$1.72+$17.2K+15.3%75.3K after
May 1, 2025 (view filing)7:07 PM ETApr 30-May 11 dayEdelman Joseph and 2 others10% OwnerSSale−736.8K$1.38−$1.02M−19.2%3.10M after2 lots
Apr 29, 2025 (view filing)7:26 PM ETApr 25-294 daysEdelman Joseph and 2 others10% OwnerSSale−1.52M$1.81−$2.74M−28.4%3.84M after3 lots
Apr 15, 2024 (view filing)8:53 AM ETApr 114 daysEdelman Joseph and 2 others10% OwnerPPurchase+2.35M$8.50+$20.0M+78.2%5.36M after
Jun 28, 2023 (view filing)3:47 PM ETJun 262 daysChione Ltd and 4 others10% OwnerSSale−16$12.93−$206.880.0%3.85M after
Jun 20, 2023 (view filing)5:15 PM ETJun 155 daysChione Ltd and 4 others10% OwnerSSale−2.06K$12.14−$25.0K−0.1%3.85M after
Jun 14, 2023 (view filing)6:33 PM ETJun 12-142 daysChione Ltd and 4 others10% OwnerSSale−5.89K$12.29−$72.4K−0.2%3.85M after3 lots
Nov 21, 2022 (view filing)6:26 PM ETNov 174 daysChione Ltd and 4 others10% OwnerPPurchase+400.0K$12.50+$5.00M+11.6%3.86M after
Nov 21, 2022 (view filing)4:31 PM ETNov 174 daysRA Capital Healthcare Fund LP and 4 othersDirector, 10% OwnerPPurchase+3.39M$12.50+$42.4M+340.8%4.38M after